Resource Summary Report

Generated by dkNET on Sep 16, 2026

J.RT3-T3.5

RRID:CVCL_1316
Type: Cell Line

Proper Citation

RRID:CVCL_1316

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1316

Proper Citation: RRID:CVCL_1316

Description: Cell line J.RT3-T3.5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood T acute lymphoblastic leukemia

Defining Citation: PMID:6208306, PMID:20164919, PMID:20215515, PMID:23637631

Comments: Characteristics: Does not express the beta chain of the T cell antigen receptor., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: J.RT3-T3.5

Synonyms: J.RT3/T3.5, J-RT3-T3-5, JRT3-T3.5, JRT3T3.5, JRT3T35, Jurkat RT3-T3.5, Jurkat/RT3-T3.5

Cross References: CLO:CLO_0006984, EFO:EFO_0002213, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, ATCC:TIB-153, BioSample:SAMN03471939, cancercelllines:CVCL_1316, Cell_Model_Passport:SIDM01263, ChEMBL-Cells:CHEMBL3308326, ChEMBL-Targets:CHEMBL2366219, Cosmic:683538, Cosmic:907391, Cosmic:1151780, GDSC:907391, GEO:GSM1669963, IGRhCellID:JRT3T35, LINCS_LDP:LCL-1014, PharmacoDB:JRT3T35_674_2019, Progenetix:CVCL_1316, PubChem_Cell_line:CVCL_1316, Wikidata:Q54898432

ID: CVCL_1316

Hierarchy: cvcl_0367

Record Creation Time: 20220427T220643+0000

Record Last Update: 20260913T004618+0000

Ratings and Alerts

No rating or validation information has been found for J.RT3-T3.5.

No alerts have been found for J.RT3-T3.5.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Ramesh KM, et al. (2026) T Cell Assay to Track Presentation of an Influenza Hemagglutinin Epitope Presented by the MHC-II Protein HLA-DR1. Methods in molecular biology (Clifton, N.J.), 3007, 255.

Viswanathan M, et al. (2026) TCR? constant usage tunes human ?? T cell antigen sensitivity, thymic programming, and peripheral function. Science immunology, 11(116), eadr7167.

Li S, et al. (2026) Lung mucosal and systemic responses at single-cell resolution in an aerosolized Mycobacterium bovis BCG human challenge model. Cell reports. Medicine, 7(6), 102830.

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. Immunity, 58(2), 431.

Conn BP, et al. (2025) Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell reports methods, 5(5), 101049.

Kondo T, et al. (2025) Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. Cell, 188(9), 2372.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.

Du J, et al. (2025) Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity. Cell, 188(15), 4025.

Sugita Y, et al. (2024) Candidate tumor-specific CD8+ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis. Oncoimmunology, 13(1), 2371556.

Amissah OB, et al. (2024) NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. Cancer cell international, 24(1), 64.

Mathewson ND, et al. (2021) Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell, 184(5), 1281.

Choi J, et al. (2021) Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell reports methods, 1(5), 100084.

Sibener LV, et al. (2018) Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding. Cell, 174(3), 672.